The Relationship of Phthalate Exposure During Pregnancy and Preeclampsia

Completed

• Conditions: Preeclampsia; Progestin; Phthalate Exposure; Estrogen
• Interventions: Other: test Phthalates, estrogen and progesterone

• Registration Number: NCT04777929
• Lead Sponsor: Second Affiliated Hospital of Wenzhou Medical University

Brief Summary

Phthalates are a group of ubiquitous synthetic endocrine-disrupting chemicals. Fetal and neonatal periods are particularly susceptible to endocrine disorders, which prenatal exposure to phthalates causes. There is increasing evidence concerning the potential endocrine disrupting for phthalate exposure during pregnancy. Prenatal exposure phthalates would disrupt the level of sex hormone in pregnant women, which results in preeclampsia. The relationship of prenatal phthalate exposure with maternal and neonatal outcomes in human beings was often sex-specific associations. Because of the potentially harmful influence of prenatal phthalate exposure, steps should be taken to prevent or reduce phthalate exposure during pregnancy.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-01
• Study First Submitted: 2021-02-28
• Study First Submitted QC: 2021-02-28
• Study First Posted: 2021-03-02
• Primary Completion: 2022-09-30
• Study Completion: 2022-10-31
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-28
• Last Update Posted: 2022-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

• Singleton pregnancy
• Term pregnancy with the gestational age of 37-40 weeks

Exclusion Criteria

• Maternal systemic diseases (hypertension disorders, immunological diseases) or pregnant complications (polyhydramnios, oligohydramnios, diabetes mellitus, intrahepatic cholestasis of pregnancy)
• Delivery before 37 weeks or after 40 weeks

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
healthy pregnant woman	test Phthalates, estrogen and progesterone	pregnant woman without any disease of pregnancy
pregnant woman with preeclampia	test Phthalates, estrogen and progesterone	pregnant woman with preeclampia but without any other disease of pregnancy

Primary Outcome Measures

Name	Time	Method
Phthalates in urine	37 weeks to 40 weeks gestation	Collect the urine of pregnant women and test the abundance of Phthalates

Secondary Outcome Measures

Name	Time	Method
The female progesterone	37 weeks to 40 weeks gestation	Collect the placenta tissue of pregnant women and test the abundance of estrogen progesterone receptor

Trial Locations

Locations (1)

department of obstetrics of Second Affiliated Hospital of Wenzhou Medical University; 🇨🇳 Wenzhou, Zhejiang, China